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INTRODUCTION 
 
ASYMPTOMATIC PERIPHERAL ARTERY DISEASE 
Def: asymptomatic peripheral artery disease is defined as ankle 
brachial index less than 0.9 in patients with no clinical evidence of 
peripheral arterial disease or foot ulcer
1
. Ankle brachial index less than 
0.9 has got 90% sensitivity and specificity. Low brachial index is a 
predictor of future myocardial events stroke and amputation. Though 
prevalence of peripheral arterial disease is high in diabetes, studies 
looking into the presence of asymptomatic peripheral arterial disease in 
diabetic patients are very few. 
 In spite of the understanding that asymptomatic peripheral arterial 
disease is a very important risk factor for all types of future vascular 
events including cerebrovascular  disease, coronary artery disease and 
critical foot ischemia which eventually leads to amputations, the interest 
towards studying such a disease seems to be minimal. 
 Ankle brachial index is a simple inexpensive diagnostic test used 
for diagnosis of peripheral arterial disease. Sensitivity is especially low in 
the elderly. Blood Pressure is measured using sphygmomanometer and 
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hand held Doppler and the ratio of Ankle Blood Pressure to Brachial 
Blood Pressure is calculated
2
.  
Epidemiological studies have demonstrated that patients with 
peripheral arterial diseases have poor survival when compared to the 
general population
3
. Diabetic patients with peripheral arterial diseases 
have even more poor prognosis compared to non-diabetic peripheral 
arterial diseases
4
. 
 Prolonged duration of diabetes, associated diseases like 
hypertension, kidney diseases, lipid abnormalities etc also seem to 
increase the atherosclerotic risk and hence peripheral arterial diseases. 
Smoking is an important risk factor for all vascular events. In peripheral 
arterial disease also, smoking forms an important risk factor for its 
development. Presence of other vascular diseases in any patient is 
indicative of atherosclerotic disease in the patient and hence possibility of 
peripheral artery disease in such patients is high. 
 This study is aimed at finding out the presence of asymptomatic 
peripheral arterial disease in diabetic individuals and comparing it with 
non diabetic population.  
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AIM OF THE STUDY 
       The aim of the study was to establish the high prevalence of 
undetected, asymptomatic peripheral arterial disease in type 2 diabetes in 
patients attending Coimbatore Medical College and Hospital. 
OBJECTIVES 
1. To establish the hypothesis that asymptomatic peripheral 
artery disease is common in diabetes. 
2. To assess the relation of asymptomatic peripheral arterial 
disease to the sex of the patient. 
3. To establish passive smoking as an additional risk factor. 
4. Risk identification and outcome prediction, thereby 
preventing complications like amputations. 
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MATERIALS AND METHODS 
Study design 
        This was a cross sectional, case- control study of patients attending 
Coimbatore Medical College with (cases) or without (controls) Diabetes 
Time period 
       August 2014 to July 2015 
Inclusion criteria 
100 diabetic patients without clinical evidence of peripheral 
vascular disease or other vascular diseases and an equal number of 
non diabetics attending hospital for other ailments were included as 
cases and controls respectively. 
Exclusion criteria 
1. Established atherosclerotic diseases like coronary artery 
disease, stroke or peripheral vascular diseases. 
2. Smokers. 
3. Patients with leg claudication or chronic leg pain syndrome. 
4. Patients with absent lower limb pulses 
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5. Bed-ridden patients. 
6. Diabetic foot ulcer patients. 
Data collection methods 
• Informed consent was taken from all the participants prior to 
examination. 
• Detailed history including duration of diabetes, vascular diseases, 
dyslipidaemia, smoking, alcohol use and drugs were noted. 
• A thorough physical examination including all peripheral pulses 
and carotid pulses were examined. 
• Blood pressure measured using aneroid/ digital 
sphygmomanometer using a stethoscope. 
• Brachial and ankle systolic blood pressures were measured using 
a hand held Doppler. 
• Routine investigations including blood sugars, lipids, RFT, and 
ECG were done. 
• Data recorded in a proforma, tabulated and statistically analyzed 
using online statistical tools.   
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REVIEW OF LITERATURE 
Diabetes Mellitus:  
Definition: Diabetes mellitus is defined as a heterogeneous group 
of diseases characterized by hyperglycemia secondary to increased 
production of glucose and / or decreased utilization or both.  
  Diabetes mellitus refers to a group of disorders presenting with 
hyperglycemia, having several distinct causes, resulting from complex 
interactions of genetic and environmental factors. Hyperglycemia results 
from decreased insulin secretion decreased glucose utilization or 
increased glucose production
5
. 
Classification
6
   
1. Type 1 Diabetes (insulin deficiency) 
A-immune mediated   B-Idiopathic 
2. Type 2 Diabetes (insulin deficiency,relative insulin deficiency-
insulin secretory defect) 
3. Other specific types of diabetes 
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A. Genetic defects of B cell function characterized by mutation in  
a. Hepatocyte nuclear transcription factor (HNF) 4 alpha (MODY 1) 
b. Glucokinase (MODY 2) 
c. HNF 1 alpha (MODY 3) 
d. Insulin Promoter Factor 1 (MODY 4) 
e. HNF 1 b (MODY 5) 
f. Neuro D1(MODY 6) 
g. Mitochondrial DNA 
h. Subunits of ATP sensitive potassium channel 
i. Proinsulin or Insulin 
B. Genetic defects in insulin action 
a. Type A insulin resistance 
b. Leprechaunism 
c. Rabson Mendenhall syndrome 
d. Lipodystrophy syndromes 
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C. Diseases of exocrine pancreas 
a. Pancreatitis  
b. Pancreatectomy  
c. neoplasia 
d. cystic fibrosis 
e. haemochromatosis 
f. fibrocalculous pancreatopathy 
g. mutations in carboxyl esterlipase 
D. Endocrinopathies: 
a. acromegaly 
b. cushings syndrome 
c. glucagonoma 
d. pheochromocytoma 
e. hyperthyroidism 
f. somatostatinoma 
g. aldosteronoma 
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E. Drug or chemical  induced 
a. glucocorticoids 
b. rodenticide –vacor 
c. pentamidine 
d. nicotinic acid 
e. diazoxide 
f. beta-adrenergic agonists 
g. thiazides 
h. hydantoins 
i. asparginase 
j. alpha-interferon  
k. protease inhibitors 
l. antipsychotics (atypical and others) 
m. epinephrine 
F. Infections 
a. congenital rubella 
b. cytomegalovirus 
c. coxsackie virus 
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G. Uncommon forms of immune mediated diabetes 
a. stiff person syndrome 
b. anti insulin receptor antibodies 
H. Other genetic syndromes 
a. wolfian syndrome 
b. down syndrome 
c. klinfelters syndrome 
d. turners syndrome 
e. freidreichs ataxia 
f. huntingtons chorea 
g. Laurence moon biedl  syndrome 
h. mytonic dystrophy 
i. porphyria 
j. Prader willi syndrome 
4. Gestational Diabetes Mellitus  
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Type2 Diabetes Mellitus 
Type2 Diabetes is a heterogeneous group characterized by 
combination of insulin resistance and insulin secretary defect associated 
usually with increased insulin production initially. Type2 Diabetes may 
be preceded by a period of abnormal glucose homeostasis manifested as a 
raised fasting blood sugar (Impaired Fasting Glucose- IFG) or an 
increased post meal (glucose) blood sugar (Impaired Glucose Tolerance- 
IGT)
5
.  
 Type2 Diabetes is ever increasing worldwide and in India, and 
more so in commonly South India
7
. By 2025 the global burden of type2 
Diabetes was estimated to rise to 270 million patients, an alarming 
situation, probably secondary to sedentary life style and resultant obesity 
  
12 
 
as per a 1998 study
8
. By 2010 Diabetes cases worldwide (type1, type2 
and others together) was estimated at about 285 million and International 
Diabetes Federation projects that 438 million people worldwide will be 
affected by Diabetes by 2030, of which, majority of course will be type2 
diabetes
6
. 
 
 More and younger individuals are affected by diabetes and people 
on their middle age are most affected by diabetes. Reason for a shift to 
left of type2 diabetes is probably sedentary lifestyle and increasing 
indulgence in junk foods. The fact that more diabetics survive for longer 
periods results in more older diabetics and more people with prolonged 
diabetes and hence more of complications.  
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Both males and females are equally affected by diabetes, and the 
numbers are increasing in both sexes over time. However the increase is 
more profound in males compared to females. 
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The burden of diabetes is not merely the number of diabetic cases, 
but the enormous cost involved in the treatment of diabetes and its 
complications. More over diabetic foot diseases result in significant 
morbidity and mortality both by itself and by associated coronary artery 
disease and cerebrovascular disease. 
Diagnostic criteria for diabetes mellitus  
1) HbA1C > 6.5% 
(Tested using a method i.e) National Glyco hemoglobin 
standardization Programme – Certified and standardized) 
2) Fasting plasma glucose level > 126 mg/dl (7.0 mmol/lit)  
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3) 2 hr. post glucose plasma glucose level > 200 mg/dl (11.1 
mmol/lit) 
4) In patients with classic symptoms a random plasma glucose level 
> 200 mg/dl (11.1 mmol/lit)  
Prediabetes 
 A fasting plasma glucose level 100-126 mg/dl is known as 
impaired fasting plasma glucose. (IFG) and 2 hr plasma glucose 140-200 
mg/dl is known as impaired glucose tolerance (IGT). 
 IFG & IGT are together called prediabetes. People with 
prediabetes have similar vascular and atherosclerotic risks as in diabetics.  
Treatment of Diabetes : 
5,6
 
 The aim of treatment of diabetes mellitus is to alleviate symptoms 
and to prevent or atleast slow down complications.  
 Glycemic control and blood pressure control are mainstay in 
control of microvascular complications (retinopathy, nephropathy). In 
prevention of macrovascular complications (coronary artery disease, 
peripheral vascular disease and cerebrovascular disease) aspirin therapy, 
smoking cessation and lipid control also play a major role in addition to 
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glycemic control and hypertension control. Glycemic control is important 
in preventing other metabolic complications also.  
Diabetic treatment consists of many interventions integrated.  
Nutritional interventions, promoting physical activity, smoking cessation, 
pshychosocial care, glycemic treatment, setting individual therapeutic 
goals, health education, early detection and treatment of complications 
and intensification of insulin therapy in type 2 diabetes mellitus. Ideal 
diabetic care is done by a multidisciplinary team comprising of diabetic 
physician, diabetic educatior, nutriontist, diabetic nurses, 
ophthalmologist, cardiologist, nephrologist, neurologist, podiatrician, and 
social workers.  
Ideal treatment target in diabetes is to maintain pre-prandial Blood 
sugar = 90 – 130 mg/dl and HbA1C < 7.00 percent.  
Diabetic treatment goals are not fixed and are dependent on other 
morbidities, risk profile of the patient and life expectancy of the patient.  
Aggressive glycemic treatment goals are not advisable for elderly 
patients, those with advanced malignancies, those with extensive 
coronary artery disease etc.  
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Whereas an young patient with no other co-morbidities can have a 
aggressive management goals as tight as HbA1C  6% 
Early treatment of diabetes mellitus can lead to longterm positive 
benefits and uncontrolled diabetes in the early stages can relentlessly 
progress to complications inspite of better glycemic control at later stage 
(Metabolic memory).  
Non pharmacologic treatment 
In many patients with diabetes intial intervention to be offered is 
lifestyle modification. Lifestyle modifications include improvements in 
physical activity, therapeutic dietary interventions and smoking cessation.  
Dietary modification 
It is of atmost importance to note that dietary interventions does 
not mean imposing undesirable and unpalatable foods which patients are 
unlikely to follow. Ideal dietary intervention should be based on locally 
available foods which suites the culture and customs of the patient.  
Caloric restriction is most important. Depending on the patients 
physical activity and actual body weight versus ideal body weight, calorie 
requirements is calculated. Modest restriction of saturated fats and simple 
sugars is needed. 5-10% weight loss if achieved is associated with 
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significant improvements in HbA1C levels, Blood pressure, triglycerides 
and increase in HDL cholesterol. And hence will result in significant 
reduction in risk of vascular disease.  
10-15% weight reduction can result in even better glycemic control 
and cardiovascular risk reduction. High protein low carbohydrate diets 
can result in better sugar control. 
Physical  activity modification  
 Increased physical activity in the form of aerobic exercise can 
improve insulin sensitivity and blood sugar values. Structured exercises 
of >150 min/week is associated with greater HbA1C reduction. However 
physical activity will help to lower blood sugar only when combined with 
dietary modifications.  
 Patient should be allowed to choose a physical activity which he or 
she is likely to continue. eg. walking, jogging, swimming. A previously 
sedentary patient should not jump into severe physical activity to start 
with. Rather a gradual start is advisable for older patients, those with long 
standing diabetes, patients with multiple risk factors and those with 
previous atherosclerotic diseases should have proper cardiac evaluation 
prior to starting exercises.  
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Pharmacologic Therapy  
 Drugs used in diabetes can be classified as follows.  
1) Biguanides  
2) Sulfonyl ureas  
3) Meglitinide derivatives 
4) Alfa-glucosidase inhibitors 
5) Thiazolidine  diaones 
6) Glucogan like peptide-I (GLP-1) agonists  
7) Dipeptidyl peptidase IV (DPP4) inhibitors 
8) Selective sodium glucose transporter II (SGLT-II) inhibitors 
9) Insulins  
10) Amylinomimetics 
11) Bile acid sequestrants 
12) Dopamine agonist 
Biguanides 
 Metformin is the only clinically used drug in this group. Another 
biguanidees, phenformin was withdrawn from the market due to high 
incidence of lactic acidosis. Metformin is time tested molecule used as 
first line therapy of type 2 diabetes. Mechanism of action is by inhibiting 
hepatic gluconeogensis. It also probably decreases peripheral insulin 
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resistance. Additional uses of metformin include treatment of polycystic, 
ovarian disease and treatment of obesity. It is relatively safe and seldom 
produces hypoglycemia by itself. Significant HbA1C reduction is seen 
with metformin especially when the initial HbA1C is very high. Side 
effects are diarrhea, flatulence and intestinal pseudo obstruction. 
Sulpfonyl ureas 
 Sulfhonyl ureas are insulin secretagogues that stimulates insulin 
secretion from pancreatic beta cells. They are highly potent and effective, 
though the actions may be short lived. There is gradual loss of beta cell 
function due to apoptosis and hence reduce insulin production. They are 
used as adjuncts to diet and exercise in type 2 diabetes possibly as add on 
to metformin. Examples glibenclamide, glipizide, gliclazide and 
glimipride side effects are hypoglycemia, allergic rashes, steven johnson 
syndrome etc.  
Meglitinide derivatives  
 Eg. Repaglinide, Nateglinide 
 They are short acting insulin secretagogues also known as 
prandial regulators. They also act in a way similar to sulfonylureas but 
the effect is more physiological and short lived. They are much more 
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costly when compare to sulfonylureas. Side effects is hypoglycemia much 
less then sulfonylureas.  
Alfa-glucosidase inhibitors 
 Examples : Acarbose, Voglibose  
 They act by inhibiting the enzyme alfa-glucosidase which 
facilitates the breakdown of complex sugars into simple sugars. Thus 
alfa-glucosidase inhibitors prevents absorbtion of carbohydrates. 
Troublesome side effect of flatulence limits their use.  
Thiazolidine diones 
 Examples : Pioglitazone, Rosiglitazone  
 They act on peroxisome proliferator activated receptor  γ. Once 
widely used they have fallen into ill repute and is sparingly used now. 
Rosiglitzone is already withdrawn from market due to inadequate cardiac 
safety. There was a hue and cry regarding bladder cancer with the use of 
pioglitazone and it was temporarily banned from an Indian market.  
 These drugs are highly effective in reducing insulin resistance 
and facilitating glucose uptake in peripheral tissues especially adipose 
tissue. Pioglitazone additionally have beneficial effects in non alcoholic 
steatohepatitis and favourable lipid regulatory effect. Pioglitazone can be 
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used as monotheraphy or in combination with metformin, sulfonylureas, 
meglitinides, DPP4 inhibitors, GLP1 receptor agonist or insulin. Side 
effects are fluid retention, weight gain, worsening cardiac failure 
fractures and probably bladder cancer. Saraglitazar a combined PPAR – 
 α and γ agonist is currently available having favourable effects on 
triglycerides and glucose.  
GLP1 agonists   
 Examples. Exenatide, Liraglutide albiglutide, Dulaglutide.  
 They act by mimicking the endogenous incretin. GLP-I. They 
stimulate glucose dependent insulin release, reduce glucagon and delay 
gastric emptying. They promote moderate weight loss. There is animal 
data suggesting that they prevent beta cell apoptosis and hence restoring 
beta cell mass, though not proven in humans. Side effects include nausea 
vomiting and abdominal discomfort.  
Liraglutide the long acting GLP-I analogue has been approved by the 
USF DA for treatment of obesity.  
Dipeptidyl  Peptidase IV inhibitors 
 Examples. Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, 
Allogliptin 
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 They act by inhibiting the enzyme dipeptidyl peptidase IV which 
is responsible for degradation of endogenous incretins, thus prolonging 
incretin effect. They can be used as monotherapy or in combination with 
metformin, thiazolidinediones and insulin.  
 They are more or less weight neutural and produce moderate 
reduction in HbA1C. Upper respiratory tract infections are increasingly 
reported with the use of DPP-IV inhibitors. Hypoglycemia is seldom 
seen.  
Selective Sodium Glucose transporter II – inhibitors  
 Examples. Canagliflozin, Dapagliflozin, Empagliflozin  
 They act by decreasing renal threshold of glucose which result in 
increased excretion of glucose in urine. They can be used in combination 
with metformin, sulfonyl ureas, DPP IV inhibitors. Their use is limited 
when the GFR is low. Increased incidence of urinary tract infection is 
seen with use of SGLT II inhibitors. 
Insulins  
 Bovine and porcine insulins were used earlier but now 
recombinant human insulins are in use. Regular Insulin is short acting and 
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is used as multiple doses for diabetes treatment and can be used as 
intravenous infusion in emergencies.  
 NPH insulins are intermediate acting and can be used as twice 
daily regimens alone or in combination with regular insulin (30/70 or 
50/50 premixed combinations are available in market). Insulin analogues 
are widely used nowadays. There are ultrashort acting insulin analogues, 
examples Lispro, Aspart and Glulysine and ultralong acting insulin 
analogues. eg. detrimer, glargine, deglutec available. 
 All patients of Type I diabetes and most of advanced Type 2 
diabetes will require insulin. Acute complications of diabetes, infection, 
pregnancy, surgeries and renal failure will require insulin therapy. 
Hypoglycemia is the dreaded side effect of insulin therapy. Weight gain 
is experienced by most of the patients with insulin therapy.  
Amylinomimetics :  
 Examples : Pramlintide acetate. Amylin is secreted by pancreatic 
beta cells. It delays gastric emptying increased postprandial glucagon 
release and causes satiety. Wide clinical experience is lacking with this 
group. 
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Bile acid sequestrants  
 Examples : Colesevelam 
 Initially developed as a lipid lowering agent subsequently found 
to have glucose lowering effects. Can be used as a adjunctive therapy to 
improve glycemic control. Side effects are abdominal discomfort and 
flatulence. 
Dopamine agonists : 
 Eg) Bromocriptine mesylate  
  Bromocriptine is a centrally acting D2 receptor agonist. When 
given as a short acting formulation in single morning dose they may act 
on circadian neuronal activities within hypothalamus to reset the 
abnormally elevated drive for plasma glucose. It do not cause weight gain 
or hypoglycaemia. Orthostatic hypotension and syncope can be 
troublesome esp. during initiation of therapy.  
Surgical treatment for diabetes – Bariatric surgery  
 In morbidly obese patients bariatric surgery has shown to 
improve diabetes control and in some patients even normalizes blood 
sugar. It is important that the patients are carefully selected for surgery.  
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Bariatric Surgeries :  
I. Restrictive  
- Vertical banded gastroplasty  
- Laparoscopic adjustable gastric banding (LAGB)  
- Jaw wiring  
II. Malabsorptive  
- Biliopancreatic diversion (BPD) 
- Biliopancreatic diversion with duodenal switch (BPD-DS) 
- Jejunoileal bypass  
III. Combined  
IV. Roux-en-Y-gastric bypass (RYGB) open or laparoscopic. 
 Rou-en-Y-gastric bypass is having best sustained effect on 
diabetes remission. 
Prevention of type 2 diabetes :  
 Prevention of type 2 diabetes mainly relies on the following  
Principles  
1. Weight reduction  
2. Therapeutic Nutritional intervention  
3. Regular physical activity  
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4. Cardiovascular risk reduction 
5. Aggressive treatment of hypertension and dyslipdemia 
 
Life style modification 
 Life style changes with 4-5% sustained weight reduction has been 
shown to decrease risk for diabetes in patients by 58%. 
 Life style modification includes caloric restriction, regular 
physical activity and cessation of smoking etc.  
Pharmacologic prevention  
 Though many drugs are tried, USFDA has not approved any durg 
for prevention of diabetes. However metformin and pioglitazone are 
shown to be beneficial in prevention of diabetes.  
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Peripheral Artery Disease 
 Peripheral artery disease is a major macro vascular complication of 
diabetes, often leading to ischemia and subsequent diabetic foot 
complications including amputations. It is highly prevalent among 
diabetics, both men and women. Symptoms of peripheral arterial disease 
include intermittent claudication, rest pain, numbness of extremities, 
parasthesias, loss of hairs, skin changes like blackish discoloration and 
gangrenes.  
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 Asymptomatic peripheral artery disease, as evidenced by ankle-
brachial index less than 0.9 is also common in diabetic men and women. 
Most of these patients can, in their later life, develop significant, 
clinically evident peripheral arterial diseases and its complications. Other 
vascular diseases are also notably high in these patients. Detection of 
peripheral arterial disease in an early stage, when asymptomatic, can help 
the clinician to decide on necessary preventive strategies like strict 
glycemic control, control of lipids, cessation of smoking, control of 
hypertension, prevention of foot infections, proper podiatric care etc and 
can reduce the progression of disease to a stage requiring amputation. 
Preventive strategies are also important in preventing other vascular 
diseases like coronary artery disease and cerebrovascular disease. 
In a South Indian study, type2 diabetic women had a high 
prevalence of asymptomatic peripheral arterial disease compared to non-
diabetic women
9
.  
 Undetected peripheral arterial disease is fairly common in type 2 
Diabetes patients with additional risk factors as evidenced by literature. 
Traditional risk factors like smoking, age and dyslipidaemia are also 
relevant in type2 Diabetes and renders increased susceptibility to vascular 
diseases. Atherosclerosis being a systemic disease, peripheral arterial 
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disease often coexists with other vascular diseases like coronary artery 
disease and cerebrovascular diseases, and hence a study of peripheral 
artery disease is ideally done with a setting where compounding risk 
factors are excluded. Other forms of vascular diseases are also excluded 
in view of their co-existence with peripheral arterial disease. 
 Age is an important determinant of atherosclerotic events. As age 
advances, all atherosclerotic events also increase. Autopsy evidence 
shows that atherosclerotic process in blood vessels starts as early as at the 
age of two years. It then progresses relentlessly to end in various forms of 
vascular events. 
 Atherosclerosis is no longer a disease of the rich. It is common 
across all socioeconomic strata. There is very little difference between the 
rich, the middle class and the poor.  
 Alcohol use cause some changes in lipids like an increase in HDL, 
which may help in decreasing the vascular events. It is important to 
remember that use of alcohol in moderation only will be helpful; which is 
seldom possible with most of the individuals. 
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Non Invasive Diagnostic Evaluation- Ankle-Brachial Index (ABI) 
 ABI is more and more used in evaluation of patients at risk of 
cardiovascular diseases. A lowABI (less than 0.9) is associated with 
increased risk of coronary events and indicates significant, even though 
asymptomatic, underlying peripheral vascular disease.  
Measuring ABI
10
:    
Blood pressure is measured in both upper limbs and the highest 
systolic pressure is taken as denominator. The ankle pressure is measured 
by keeping BP cuff above the ankle, assessing the return to flow of the 
dorsalis pedis and posterior tibial arteries using a pencil Doppler probe 
over each artery. Thus measured ankle pressure becomes the numerator. 
The ratio of ankle pressure to highest arm systolic pressure estimates the 
ankle brachial index (ABI), normal being more than 1. Patients with 
intermittant claudication usually have an ABI in the range of 0.5-0.7 and 
those with rest pain are in the range 0.3- 0.5. An ABI less than 0.3 is 
usually noted in those with gangrene. These values can change, 
depending on the degree of compressibility of the vessel wall. The test is 
having little value in heavily calcified vessel. Due to non-compressibility 
of blood vessel as certain cases of diabetes and end stage renal disease 
can have ABI of 1.4 or more and will require additional tests to evaluate 
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Peripheral Arterial Disease (PAD). Alternate tests include toe-brachial 
pressure, pulse volume recordings, transcutaneous oxygen measurements 
or vascular imaging (duplex ultrasound).  
   
  Higher of the ankle systolic pressure
  Higher arm systolic pressure
 
 Ankle brachial index has a 90%sensitivity and specificity in 
identifying peripheral artery disease when value less than 0.9 is taken as 
diagnostic.
11 
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 Possible errors in measurement of ABI 
1. Observer error: Reading can change from person to person, 
especially so in inexperienced hands. This can be overcome by 
experienced physician / technician doing the test. 
2. Instrument related errors: There can be minor variations in the 
measured ABP depending on the quality of instrument used. 
Properly standardized good quality instruments can avoid this 
error. 
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3. Patient related errors like certain drugs, cold exposure, smoking, 
stress, physical factors etc should be properly evaluated and 
excluded. 
4. Environmental factors: All tests needs to be done in similar 
environmental conditions to avoid any possible errors. 
Pathogenesis of Peripheral Artery Disease in Diabetes
12 
 Pathogenesis of chronic diabetic complications is a process that 
occurs in stages over a period of years. Hyperglycemia remains the core 
the issue with secondary contributory factors like hypertension, 
hyperlipedaemia, smoking, alcohol use, dietary excess or deficiency or 
other environmental toxins. Once structural changes set in further 
progression to end stage disease is independent of hyperglycemia and 
there could be some genetic determinants also.                         
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Hyperglycemia can result in tissue damage through various 
pathways
13
: 
1. Increased Polyol pathway flux- resulting in formation of 
polyalcohol, sorbitol by enzyme aldose reductase. The percentage 
of this pathway in hyperglycemia varies from species to species 
and site to site. Normally sorbitol is converted to fructose by 
sorbitol dehydrogenase. But in hyperglycemia, when sorbitol 
levels are high, conversion to fructose becomes ineffective and 
accumulation of sorbitol results in osmotic stress. Aldose 
reductase inhibitors like tolrestat and epalrestat act by inhibiting 
the enzyme aldose reductase, thereby reducing sorbitol production. 
2. Increased intracellular Advanced Glycation End products. 
Advanced glycation end products are found in extracellular 
structures of Diabetic retinal vessels and renal glomeruli. They 
probably arise secondary to intracellular hyperglycemia, leading to 
formation of reactive carbonyls(methyl glyoxal and glyoxal) 
which combines with extracellular proteins. These advanced 
glycation end products thus formed will alter intracellular protein 
function, interfere with normal matrix-matrix and matrix and 
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matrix-cell interactions and also results in pathological changes 
gene expression, thus resulting in tissue damage. 
3. Activation of Protein kinase C: Intracellular hyperglycemia results 
in increased levels of di-acyl glycerol (DAG), formed from 
glycolysis intermediate, glyceraldehydes-3- phosphate. DAG 
activates protein kinase C (PKC), especially the β and δ isoforms. 
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All these mechanisms will result in changes that will finally result 
in chronic complications, both micro and macro vascular. 
Vascular changes include changes in flow rate, changes in vascular 
permeability, endothelial dysfunction, pro-coagulability and 
degeneration. 
Dilatation 
Growth inhibitors       Constriction 
Anti thrombosi    Anti inflammation  
Growth promotion    Prothrombosis 
Proinflamation                            
 
                
 
 
  
         Endothelial dysfunction 
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Lipid abnormalities in Diabetes
14 
 Being an anabolic hormone, insulin promotes esterification of fatty 
acids, uptake of glucose in adipose tissue as well as liver and muscles, 
and conversion of glucose to glycogen. Hormone sensitive lipase activity 
in adipose tissue is inhibited by insulin. In insulin deficient states, there is 
extensive mobilization of fatty acids from adipose tissue and lipolysis 
which leads to ketone formation and ketoacidosis. 
 UKPDS ( United Kingdom Prospective Diabetes study has shown 
that hypertriglyceridaemia is already present at the time of diagnosis of 
type2 diabetes
15
. This may be caused by additional factors like 
hypothyroidism, obesity and other genetically determined lipid 
abnormalities. Type2 diabetes is also characterized by a low HDL. 
Coronary morbidity and mortality are high when cholesterol levels are 
higher in both diabetic and non-diabetic individuals, especially the 
nonHDL cholesterol
16
. But at similar levels of cholesterol and LDL, 
diabetics are at a greater risk of vascular disease, probably due to 
qualitative changes in lipoproteins. Diabetics have a greater glycation of 
their LDL. Diabetics also seem to have more of small LDL which seems 
to be more atherogenic. 
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 Dyslipidaemia in diabetes is closely correlated to the glycaemic 
control. The characteristic lipid abnormality, namely hyper 
triglyceridaemia often decreases with glycaemic control. 
 Abnormal lipids contribute in a major way in the development of 
vascular diseases in diabetes including peripheral vascular diseases, their 
progression, development of complications and outcome. 
Peripheral arterial disease in Diabetes   
  Peripheral artery disease is an important health care problem due to 
high incidence and prevalence as well as its complications. A number of 
clinical and epidemiological studies have shown the association of 
cumulative peripheral arterial disease incidence with duration of diabetes 
and patients age. There include Framingham (n = 4317)
17,18
, UGDP  
(n= 619)
19
, Rochester (n=1703)
20
, Kristian stand (n=374)
21
, Munchen 
(n=623)
22
, Oxford (n=186)
23
, Pittsburg (n=657)
24
 and Zagreh (n=200)
25
. 
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STUDY INCIDENCE PREVALENCE 
Framingham 
(n=4317) 
Claudication 
M=12.6/1000yrs 
F= 8.4/1000yrs 
18.8 (diabetes duration 16 
yrs) 
UGDP(n=619)  Palpation M=34.5% 
F=37.6% 
Claudication M=37.7% 
F=24.3% 
Diabetes duration 20yrs 
Rochester (n=1073) Pulse 
M=21.3/1000yrs 
F= 17.6/1000yrs 
15% (diabetic duration 10 
yrs) 
45%(diabetic duration 
20yrs) 
Kristian stand  Pulse 16.4 (DM duration 
1.5 yr) 
38.7(DM duration 2yrs) 
Munchen (n=623)  Ultrasound M=18.0% 
F=14.4% 
Oxford(n=186) Claudication 
16/1000yrs 
 
 
Pittsburg (n=657)  M=11.0% 
F>30% (DM duration >30 
yrs) 
Zagreb(n= 200)  Plethysmography :15% 
DM duration % yrs 
18.5% DM duration 10 yrs 
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Prevention of peripheral vascular disease 
 Glycemic control is the most important intervention in prevention 
of peripheral vascular – disease as well as coronary  vascular diseases and 
cerebral vascular diseases.  
 Other pharmacologic intervention include aspirin, statins and 
ACE inhibitors.  
Amputations 
 Diabetes is the leading cause of non-traumatic amputation of 
extremities in the world. About 1.8 million Americans are living with 
amputations.  Reasons for foot complications in Diabetes include 
neuropathy, pressure ulcers, skin changes and ischemia secondary to 
peripheral arterial disease.  
 Most literature reveals that vascular causes account for majority of 
amputations are due to vascular causes followed by trauma. Malignancy 
forms a minor cause of amputations. Arterial disease is major vascular 
reason for amputations. 
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 Disease wise cause of amputations in literature puts diabetes as the 
major cause followed distantly by trauma. 
Aims of aimputation  
1) To excise all pathology  
2) To restore the all maximal limb function  
Indication  
1. Vascular disease  
- Arterial  
- venous  
2. Diabetes – 85% of amputation are due to combined diabetes and 
vascular diseases.  
3. Trauma 
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4. Tumours 
5. Infection 
6. Neurological causes 
7. Congenital problem 
 
Many risk factors are associated with the chain of conditions and 
events leading to lower extremity amputation in diabetes. Modification of 
some of these risk factors by affected subjects and healthcare workers 
may reduce the risk for amputation and thus decrease the human suffering 
and monitory loss that follow amputations in very common, chronic 
disease like diabetes.
26 
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Amputations in diabetes can vary from disarticulation of toes, 
Syme’s amputations, ankle level amputations, below knee amputations, 
above knee amputations and hip disarticulation. 
Most common type of amputation in the foot is ray amputation of 
the affected toe, usually along with the distal half of the corresponding 
metatarsal. Wound is often left open as this procedure is usually done in 
infected foot, facilitating drainage. 
 
 Midtarsal amp
hind foot perfusion.
plantar flap is used 
The classical
1842. Syme’s ampu
particularly useful 
about 5cm short 
Modifications of ori
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utations are done for distal gangrenes
 In this heel is preserved for weight bea
in these cases. 
 ankle amputation was first describe
tation results in a weight bearing
in young individuals. Though the resu
of ground, patient can walk witho
ginal Syme’s procedure, where the
 with adequate 
ring. A longer 
 
d by Syme in 
 stump and is 
ltant stump is 
ut prosthesis. 
 distal articular 
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surface of tibia is left intact and a bigger plantar flap is used, results in 
better stump length. 
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Below knee amputations are the most common procedure done for 
peripheral arterial diseases. 15cm of tibia is left behind ideally. If the 
tibial length is less than 8cm, prosthesis fitting may become troublesome. 
A long posterior flap, 1.5 times the diameter of  the leg is used as the 
anterior flap will have a poorer blood supply. Posterior flap muscles are 
cut in such a way that only thin layer of gastrocnemius remains. 
 
 
 Disarticulation
end weight bearing
unacceptable bulbou
preferred. 
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Above knee amputations are common in ischemic peripheral 
arterial diseases. General dictum is that, longer the stump better is the 
results. Ideally 70% of the femur, i.e.25-30cm from tip of greater 
trochanter is retained. Anterior and posterior flaps are equal or a longer 
anterior flap is used. Hamstrings are sutured to quadriceps for equal 
muscle action.  
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Gas gangrene is a dreaded complication especially of above knee 
amputations for ischaemia. 
 
 
 Radical hip 
femur cannot be pr
classical methods 
poster flap method.
muscles are divided
short. Capsule is divi
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Hindquarter amputation is a mutilating radical amputation usually 
done for advanced malignancies. In peripheral vascular diseases it may be 
done for failed above knee amputations. Fortunately this disfiguring 
procedure is rarely done. 
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Complications of amputation  
Early complications  
1. Haemorrhage 
2. Haematoma 
3. Inection  
4. Gas gangrene  
5. Wound dehiscence 
6. Gangrene of flaps 
7. Deep vein thrombosis  
8. Pulmonary embolism  
Later complication  
1. Unresolved infection 
2. Bone spur 
3. Scar adherent to bone  
4. Amputation neuroma 
5. Phantom limb 
6. Phantom pain 
7. Ulceration of stump 
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Socioeconomic implications of amputation 
Amputations result in physical mental and economic difficulties to 
the patient and to the society. Sudden loss of mobility or major functions 
in a previously active individual will result in depression in majority of 
patients. Loss of productive life results in major economic bereavement 
both to the individual and to the community. 
Post amputation rehabilitation is a very important part of the total 
diabetic treatment. Indirect losses like loss of productive life, loss in 
wages, compensations etc will account for about 1/3
rd
 of total diabetic 
budget of the country.   
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Prevention of amputations 
Prevention of foot ulcers in diabetes can be done by testing for loss 
of sensation, done easily in the primary care clinic with a short history 
and the Semmes-Weinstein monofilament. Diabetic speciality clinics may 
check for neuropathy using biothesiometry, plantar foot pressure 
measurements, and check lower limd arterial status with hand held 
Doppler and measurement of ankle-brachial indices. These 
measurements, along with other clues from the history and clinical 
evaluation, help practitioners to stratify patients based on risk and to 
determine the type of intervention. Health education about correct 
methods of foot care and regular foot examinations are effective methods 
to prevent diabetic foot. Additional interventions which are effective 
include optimizing diabetic control, stopping smoking habit, intensive 
podiatric care, proper care of calluses, proper fitting foot wears avoiding 
injuries and certain types of prophylactic foot surgery. The value of 
various types of prescription footwear for ulcer prevention is not clear.
27
  
 Significant amount of evidence supports screening all patients with 
diabetes to identify those at risk for diabetic foot. These patients might 
benefit from certain prophylactic interventions, including patient 
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education, prescription footwear, intensive podiatric care, and evaluation 
for any surgical interventions as needed. 
Among persons diagnosed as having diabetes mellitus, the lifetime 
risk of developing a foot ulcer is estimated to be 15%
28
. 
 Peripheral arterial disease is most readily detected by the ankle-
brachial index (ABI), which is the ratio of systolic blood pressure in the 
ankle to that in the brachial artery. An ABI of 0.90 or less suggests 
peripheral vascular disease, while higher than 1.1 may represent a falsely 
elevated pressure caused by medial arterial calcinosis. This test is easily 
performed, objective, and reproducible.
29
 One large study found that the 
ABI was strongly related to the risk of foot ulceration (0.3 higher ABI is 
associated with an RR of 0.83; 95% CI, 0.73-0.96; P = .01).
30
  
Other vascular diseases and their relation to peripheral arterial 
disease. 
 Cardiovascular diseases and strokes are more common in diabetes 
when compared to non-diabetic individuals. Diabetes mellitus as such, 
markedly increases the risk of myocardial infarction, stroke, amputation, 
and death. The metabolic abnormalities caused by diabetes induce 
vascular dysfunction that predisposes this patient population to 
atherosclerosis. Control of blood pressure, lipid-lowering treatment, 
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angiotensin-converting enzyme inhibitors, and antiplatelet drugs 
significantly reduce the risk of cardiovascular events. Though  diabetic 
patients also undergo revascularization procedures due to acute coronary 
syndromes or critical limb ischemia, the outcomes are less promising than 
in nondiabetic people.
31
  
 Presence of peripheral artery disease, symptomatic or 
asymptomatic, increases the risk of coronary artery disease and 
cerebrovascular disease as part of generalized atherosclerosis. 
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There are several mechanisms by which accelerated atherosclerosis 
occur in diabetes. Hypertension, abnormal lipids and insulin resistance 
contribute to the development of atherosclerosis. Hyperglycemia plays a 
central role in the development of atherosclerosis as evidenced by the 
occurrence of increased atherosclerosis in persons with poor diabetic 
control. The overwhelming evidence in literature emphasizes the role of 
glycemic control  as the best possible intervention in the prevention of 
diabetic complications, both acute and chronic, including peripheral 
arterial disease. 
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RESULTS 
 
 A total of 100 diabetic patients (cases) and 100 non-diabetic 
controls participated in the study. All the 100 cases had more than one 
year type2 diabetes history. Ankle Brachial Index was measured for all 
200 participants (both cases and controls). 20 persons (10%) had ABI 
value <0.9. prevalence off low ABI was significantly higher in diabetics 
in comparison with non-diabetic controls. (16% vs 4%) 
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Table-1  
Age distribution 
 
 DM 
N=100 
No DM 
N=100 
p-value 
Age 51.9 
(+/-11.18) 
61.37 
(+/-9.56) 
<0.001 
 
Chart-1  
Age distribution 
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Table 2: 
omatic PAD as evidenced by ABI<
 
Total 
N=200 
DM 
N=100 
Non DM
N=100 
 (10%) 16(16%) 4 (4%) 
Chart 2: 
omatic PAD as evidenced by ABI<0
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Table 3: 
tion of PAD in Diabetic and Non Di
 
betic 
100 
<0.9) 
Non DM 
N=100 
(ABI<0.9) 
Total 
N=200 
(ABI<0.9) 
(13) 64 (3) 142 (16) 
 (3) 36 (1) 58 (4) 
Chart 3: 
tion of PAD in Diabetic and Non Di
20
40
60
80
abetic 
 
P 
0.0478 
(S) 
0.2939 
(NS) 
abetic 
 
PAD
no PAD
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         In univariate analysis, age, hypertension, obesity and metabolic 
syndrome were all associated with low ABI. 
 
            Our cohort contained more females than males, probably as a 
result of the exclusion criteria of tobacco use. The difference between 
diabetic and non-diabetic women in the prevalence of PAD was 
statistically significant (p=0.0478), where as the same in men was not 
statistically significant (p=0.2939).  Also, PAD was more common in 
women both diabetic and non diabetic. This is an important observation 
when the fact was that a number of these women were passive smokers as 
their spouses where smoking. 
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Table 4 : 
Relationship of passive smoking with PAD in women 
 
Women 
PAD 
No DM 
PAD 
DM 
No PAD 
DM 
No PAD 
No 
DM 
Total 
Passive 
Smoking 
2 9 27 28 66 
No smoking 1 4 38 33 76 
Total 3 13 65 61 142 
 
Chart 4 : 
Relationship of passive smoking with PAD in women 
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DISCUSSION 
According to data collected, there are only a few studies looking 
into the association of asymptomatic peripheral artery disease to diabetes; 
though there are a number of studies looking into the association of 
symptomatic disease with diabetes.  
A study by Carlos Lohos etal
32
 demonstrated the association 
between metabolic syndrome asymptomatic peripheral artery diseases, 
without cardiovascular disease.  
In this study all patients with evidence of any significant vascular 
disease were excluded. 
Another study
33
 looked into the association of metabolic syndrome 
and peripheral artery disease in patients already having cardiovascular 
disease, Peripheral artery disease diagnosis being done by measurement 
of ankle brachial index <0.9. 14% had low ABI in metabolic syndrome 
group whereas 10% of those without metabolic syndrome had low ABI. 
Yet another study
34
 of peripheral artery disease in diabetes reported 
12.6% incidence of asymptomatic PAD 
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A study in South Indian women with type2 diabetes
9
, 
asymptomatic PAD was reported in 19% of diabetic women when 
compared non-diabetic women of similar age group.  
In this study also there were more women included and the 
incidence of peripheral arterial disease was significantly more in females. 
REGICOR investigators demonstrated a 4.5% prevalence of 
peripheral arterial disease in general population adults
35
. 
Classical risk factors like age, dyslipidaemia, hypertension are 
often associated with low ABI
36,37,38
. Many conditions associated with 
diabetes like low HDL, high Triglycerides, high LDL, metabolic 
syndrome etc are associated with high incidence of low ankle brachial 
index and peripheral arterial disease
39
. 
As per a study by Elizabeth Selvin and Thomas P Erlinger
40
, 
peripheral arterial disease prevalence in adults more than 40 years in the 
USA was 4.3% (95% CI 3.1% to 5.5%), which translates to ≈5 million 
persons (95% CI 4 to 7 million). The prevalence was 14.5% (95% CI 
10.8% to 18.2%)in elderly, ie those more than 70 years. Black 
race/ethnicity (OR 2.83, 95% CI 1.48 to 5.42) active smoking (OR 4.46, 
95% CI 2.25 to 8.84), diabetes (OR 2.71, 95% CI 1.03 to 7.12), 
hypertension (OR 1.75, 95% CI 0.97 to 3.13), hypercholesterolemia (OR 
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1.68, 95% CI 1.09 to 2.57), and low kidney function (OR 2.00, 95% CI 
1.08 to 3.70) were positively associated with prevalent PAD in age and 
sex adjusted multivariate analysis. 
Gender difference was variable in published literature. In a review 
by Higgins and Higgins,
41
 in women 45 to 93 years of age had a 3% to 
29% (over this span of 5 decades) prevalence of peripheral arterial 
disease. But, it was evident that peripheral arterial disease was common 
in diabetic women. Most of these studies were done with cohort including 
smokers also. More men than women were smokers and hence, naturally 
men had higher incidence of peripheral arterial disease. We excluded all 
smokers, both men and women and found that women had higher 
incidence of peripheral arterial disease in both diabetic and nondiabetic 
populations, which was probably related to passive smoking as shown by 
the analysis. 
Allison et al
42
, showed that the prevalence of peripheral arterial 
disease increased with age for both men and women. More than just 
definitions, any atherosclerotic disease had higher occurrence, i.e., 
increase in the population “burden” of these diseases (defined as the total 
number of individuals who have the disease).  
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Age, the most traditional risk factor for peripheral arterial disease 
was seen to increase incidence
43
. However in our study, diabetic 
population was younger than control population (p<0.001). 
ABI is useful as a marker for atherosclerotic risk factors and also 
vascular diseases in other vascular beds. Low ankle-brachial index is 
associated with a number of other risk factors, like hypertension, type2 
diabetes, dyslipidemia, history of smoking, and several other 
cardiovascular risk factors (e.g., high sensitivity CRP, interleukin-6, 
homocysteine, and chronic kidney disease)
44
. 
Death and the composite end points of stroke or myocardial 
infarction (MI) occurred in 8.4% and 11.6% of patients. Bad prognosis 
was noted in patients with prior history of CHD, extremes of age, people 
with diabetes and a low ankle brachial index as shown by a report from 
United Kingdom by Gerard Stansby, MChir et al
45
. 
As a marker of future cardiovascular events, stroke events and 
amputations; asymptomatic peripheral arterial disease is an important, 
simple clinical tool, though terribly underutilized. More and more studies 
in the field will overemphasize the utility of ankle-brachial index as a 
regular screening procedure in diabetics with high sensitivity and 
specificity preventing future morbidity and mortality.  
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        Higher incidence of peripheral arterial disease in diabetes was 
demonstrated previously in a number of studies and is a well known 
factor. Higher incidence of asymptomatic peripheral artery disease 
demonstrated in our study is in concordance with available previous 
studies.   
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SUMMARY 
  
 Diabetes mellitus is a very common disease all over the world 
and especially so in India. Peripheral arterial disease is a very common 
macro vascular complication of diabetes and can result in morbidities like 
chronic ulcers, amputation etc.  
 Ankle-brachial index, the ratio of ankle pressure to the brachial 
pressure is an easily done clinical test with sufficient sensitivity and 
specificity and is easily reproducible. 
 Only simple tools like sphygmo manometer and a doppler probe 
are required for doing this test. A low ankle brachial index diagnoses 
asymptomatic peripheral arterial diseases in patient who are otherwise 
asymptomatic. 
 100 patients with diabetes and 100 controls without diabetes were 
included in this study. All those with  pre existing peripheral arterial 
diseases, leg ulcers, claudication, chronic leg pain syndrome coronary 
artery disease and stroke were excluded. All tobacco users were also 
excluded.  
• Age wise diabetic patients were younger (Mean 51.9 + 11.18 
years) than non diabetics (Mean 61.37 + 9.56 years). 
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• 16 (n = 100) diabetic patients and 4 (n = 100) non diabetic patients 
had ABI < 0.9 (P = 0.0095). 
• Both the cohorts consisted mostly of females (all tobacco users 
were excluded) females had higher incidence of peripheral arterial 
diseases (female 13/78 vs 3/64 P = 0.0478) (males 3/22 vs 1/36 P 
=0.2939) 
 Passive smoking assessed by the presence of active smoker in 
family was seen in 66 out of 142 women in the study ((36 diabetics and 
30 non diabetics)and peripheral arterial disease was common in these 
passive smoker both in diabetics (9/36) non diabetics 2/30) 
 Inference of this study is that asymptomatic peripheral artery 
diseases is common in diabetics and among diabetics more common in 
females. Passive smoking is an important risk factors for females with 
peripheral artery diseases. 
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CONCLUSIONS 
1. Peripheral artery disease is common in diabetes, both men and 
women. 
2. The condition may not be detected in many patients due to absence 
of signs and symptoms even when the blood flow limitation is 
significant. 
3. Though asymptomatic, these patients with low ABI are potentially 
at risk of developing ischemic limb and associated complications.  
4. Other vascular complications like coronary artery disease and 
cerebrovascular disease are also fairly common in these patients 
and hence detection of asymptomatic disease is important to 
prevent complications.  
5. Females were more included in the study as a result of the 
exclusion criteria, smoking, which excluded most men. However, 
among those included, men had a lower incidence of peripheral 
arterial disease compared to females. Analysis of history revealed 
that most of these females had a smoking partner at home, making 
these ladies passive smokers. 
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APPENDIX 
PROFORMA 
INCIDENCE OF ASYMPTOMATIC PERIPHERAL ARTERY 
DISEASE IN TYPE 2 DIABETES IN A TERTIARY CARE 
HOSPITAL 
1. Name of the Patient :  
2. Age : 
3. Sex :  
4. Address :  
5. Income :  
6. Diabetes : Yes / No  
If yes …………………. year  
7. History of HT / CAD / CVA / POVD / Diabetic Ulcer  / 
Dyslipidaemia / Renal Failure  
8. Treatment History : Atorvastatin / Betablocker  
9. Smoking : Actve / Passive / None  
10. Other Tobacco use  
11. Alcohol Use  
12. Examination Anaemia   Oedema  
13. Pulse Rate              Peripheral Pulses  Vessel Wall 
14. CVS Examination 
15. Nervous System          Peripheral Neuropathy – Position Sense 
Vibration Sense Monofilament 
16. Abdomen & Respiratory System 
17. Blood Pressure (Mannometer & Stethoscope)  
18. Brachial Pressure with Doppler 
19. Ankle pressure with Doppler 
20. Ankle brachial index 
21. Egg 
22. Lipid Profile 
23. FBS PPBS UREA CREATININE 
  
CONSENT FORM 
 
 I am Dr. VINODINI .C, carrying out a study on the  
topic “INCIDENCE OF  ASYMPTOMATIC PERIPHERAL 
ARTERY DISEASE IN  TYPE 2  DIABETES  IN  A  TERTIARY  
CARE  HOSPITAL” in Government Medical College and Hospital, 
Coimbatore conducted by Dr. C. Vinodini, Post Graduate Student in 
General Surgery Department, Coimbatore Medical College you satisfy 
eligibility criteria for inclusion. You can feel free to ask any question or 
seek any further clarification on the study and clear any doubts that you 
may have, before agreeing to participate.  
My research project is being carried out under the Department of  
General Surgery, Coimbatore Medical College and Hospital, Coimbatore. 
RESEARCH BEING DONE: 
To determine the Incidence of asymptomatic Peripheral Artery Disease in  
Type 2  Diabetics with the help of BP apparatus and hand-held Doppler, 
calculating the Ankle Bracheal Index.  
PURPOSE OF THE RESEARCH  
To find out the incidence of asymptomatic peripheral artery disease in 
type 2 diabetic individuals and compare it with general population.  
  
PROCEDURE INVOLVED  
Ordinary digital sphygmomanometer and a hand-held Doppler device are 
used to measure brachial and ankle blood pressure. Diabetic control is 
assessed as per the blood sugar reports. No invasive tests or treatments 
will be undertaken as part of study.  
DECLINING FROM PARTICIPATING  
You are hereby made aware that, participation in this study is purely 
voluntary and honorary and that you have the option and right to decline 
from participation in the study.  
PRIVACY AND CONFIDENTIALITY  
You are hereby assured about the privacy. Privacu of the subject will be 
respected and any information about you or provided by you durin study 
will be kept strictly confidential.  
AUTHORISATION TO PUBLISH RESULTS  
Results of the study may be published for scientific purposes and/or 
presented to scientific groups, however you will not be identified; neither 
will your privacy breached 
  
STATEMENT OF CONSENT 
 
I, _____________________, do hereby volunteer and consent to 
participate in this study being conducted by Dr. C. VINODINI. I have 
read and understood the consent form / or it has been read and explained 
to me in my own language. The study has been fully explained to me, and 
I may ask questions at any time. 
 
Signature / Left Thumb Impression of the Volunteer Date:          
Place: 
 
Signature and Name of witness     Date:          
Place: 
 
Signature of the investigator: 
Name of the investigator:  
  
xg;g[jy; g; [ ;; [ ;; [ ; otk;;;; 
 
bgah;  : 
ghypdk;  : 
Kfthp   :     taJ    : 
 
muR nfhit kUj;Jtf; fy;Y}hpapy;/ bghJ mWit rpfpr;ir 
Jiwapy;/ gl;l nkw;gog;g[ gapYk; khztp kU. tpndhjpdp mth;fs; 
nkw;bfhs;Sk; "rh;f;fiu nehahspfspy; vj;jid ngUf;F 
mwpFwpapy;yhj ,uj;j ehs neha; cs;sJ" vd;w nrhjidapd; 
bra;Kiw kw;Wk; midj;J tpgu';fisa[k; nfl;Lf;bfhz;lJld;/ 
vdJ midj;J re;njf';fisa[k; bjspt[g;gLj;jpf;bfhz;nld; 
vd;gij bjhptpj;Jf; bfhs;fpnwd;. 
ehd; ,e;j Ma;tpy; KG rk;kjj;JlDk;/ Ra rpe;jida[lDk; 
fye;J bfhs;s rk;kjpf;fpnwd;. 
,e;j Ma;tpy; vd;Dila midj;J tpgu';fSk; 
ghJfhf;fg;gLtJld;/ ,jd; Kot[fs; Ma;tpjHpy; 
btspaplg;gLtjpy; vdf;F ve;j Ml;nrgida[k; ,y;iy vd;gij 
bjhptpj;Jf; bfhs;fpnwd;. ve;j neuj;jpYk; ,e;j Ma;tpy; ,Ue;J 
tpyfpf;bfhs;s vdf;F chpik cz;L vd;gija[k; mwpntd;.  
 
,lk;  ;;; : 
njjp  :      ifbahg;gk;; ;; ;; ; /   nuif 
  
MASTER CHART 
CASES 
S.No Name  Age Sex ABI PS/NS 
1 Krishnaveni  42 F 1 PS 
2 Malathi 46 F 1.2 NS 
3 Suganthi  62 F 1.156 NS 
4 Krishnan 38 M 1.3 NS 
5 Gopi 54 M 0.86 NS 
6 Kanchana 51 F 0.82 PS 
7 Esrael 56 M 1.16 PS 
8 Gokila 50 F 1.07 NS 
9 Sankar 72 M 0.9 NS 
10 Sowdambika 44 F 1.15 NS 
11 Revathy 69 F 0.842 PS 
12 Sankari  48 F 1.33 NS 
13 Latha 67 F 0.85 NS 
14 Veni 75 F 1.07 PS 
15 Sarawathi 42 F 1.36 NS 
16 Lakshmanan 56 M 1.45 NS 
17 Getha 55 F 0.9 PS 
18 Krishnagounder 70 M 0.94 NS 
19 Sudha 43 F 0.85 NS 
20 Ramasamy 60 M 1.43 NS 
21 Kittan 63 M 0.93 NS 
22 Jaisankar 57 M 1.89 NS 
23 Tamilseli 70 F 1.25 NS 
24 Parvathi 35 F 0.87 PS 
25 Sreenivasan 65 M 0.97 NS 
26 Durga 68 F 0.57 PS 
27 Ruckmani 57 F 1.07 PS 
28 Poovathal 47 F 0.88 NS 
29 Elango  50 M 0.96 NS 
30 Lakshmi 38 F 1 PS 
31 Santhi  41 F 1 PS 
32 Kathirvel 50 M 1.07 NS 
33 Chinnasamy 42 M 1.33 NS 
34 Usha 53 F 1.45 NS 
35 Nanthini 50 F 0.93 PS 
36 Thulasi  40 F 1.07 NS 
37 Pappammal 49 F 1.2 NS 
38 Nagaraj 60 M 1.07 PS 
39 Ramathal 49 F 1.08 PS 
40 Pankajam 58 F 1.12 NS 
41 sivajothi 40 F 1.06 NS 
42 Ramakkal 42 F 0.92 PS 
43 Renuga 60 F 0.95 NS 
44 Balu 75 M 1.35 NS 
45 Banumathy 48 F 1.16 NS 
46 Devaki 42 F 1.19 NS 
47 Krishnammal 75 F 1.86 NS 
48 Arumugam 53 M 1 PS 
49 Devi 66 F 0.79 NS 
50 Papai 57 F 1.29 NS 
51 Swaminathan 51 M 1.36 NS 
52 Thilaga 38 F 1 PS 
53 Hyanemicha 41 F 0.82 PS 
54 grachy 60 F 0.9 PS 
55 Sarasakka 57 F 1 NS 
56 Backiyam 65 F 1.29 NS 
57 Kumari 62 F 1.16 PS 
58 Murugesh 68 M 1.2 NS 
59 Ambika 62 F 1.25 PS 
60 Jaya 54 F 1.125 PS 
61 Govindan 45 M 1.214 NS 
62 Manickam 60 M 1.57 NS 
63 Navaneetham 54 F 0.88 NS 
64 Chellakkal 64 F 1.5 NS 
65 Sarawathy 57 F 1.09 PS 
66 Indira 67 F 0.8 PS 
67 Selvaraj 50 M 0.8 NS 
68 Banumathy 54 F 0.93 NS 
69 Shantha 60 F 1.067 NS 
70 Jagathambal  63 F 1 PS 
71 Mrijeebunisha 66 F 1.2 PS 
72 Kaliyamma 55 F 1.412 NS 
73 Ganga 59 F 1.15 NS 
74 Gopinath 33 M 1.2 NS 
75 Savithri 42 F 0.96 PS 
76 Gomathi  43 F 0.93 PS 
77 Karthika 35 F 1.89 NS 
78 Malini 39 F 1.25 NS 
79 Subbammal 62 F 0.76 PS 
80 Revathi 32 F 0.94 PS 
81 Thulasi  44 F 1.45 NS 
82 Valli 32 F 1.36 NS 
83 Lathadevi 38 F 1.45 NS 
84 Mariamma 56 F 0.86 NS 
85 Devipriya 46 F 0.93 NS 
86 Hamsathbegam 58 F 0.85 NS 
87 Julie 50 F 0.95 NS 
88 Mary 43 F 1 PS 
89 Lakshmi 34 F 1.07 PS 
90 Kanagam 48 F 1.33 NS 
91 Gowri 41 F 0.97 NS 
92 Krishnakumari 64 F 0.78 PS 
93 Bakiyalakshmi 34 F 1.29 NS 
94 Gomathi  43 F 1.16 NS 
95 Parithunisha 55 F 0.8 PS 
96 Rohini 35 F 1 NS 
97 Kaliyammal  50 F 0.94 PS 
98 Fathimabeevi 43 F 1.066 PS 
99 Sivasankari 48 F 1.15 NS 
100 Sowmya 36 F 0.96 PS 
 
  
CONTROL  
S.No Name Age Sex ABI PS/NS 
1 Kannan 74 M 1.25 NS 
2 Sugantha 60 F 1.43 NS 
3 Srikumari 50 F 0.9 PS 
4 Jaya 42 F 1.36 NS 
5 Gopalsamy 68 M 0.94 NS 
6 Janaki 63 F 0.93 PS 
7 Ganga 59 F 1.2 NS 
8 Ismail 65 M 1.1 NS 
9 Marathal 72 F 0.98 PS 
10 Mohan 44 M 1.21 NS 
11 Mariammal 65 F 1.45 PS 
12 Ramachandran 53 M 1 NS 
13 Palana 41 F 0.99 PS 
14 Pappathi 75 F 0.96 PS 
15 Sivasankari 66 F 1.2 NS 
16 Kuttiakka 58 F 1.14 NS 
17 Ramkumar 54 M 1.18 NS 
18 Pankajamma 72 F 1.22 NS 
19 Paramasivam 43 M 0.99 NS 
20 Periyakka 75 F 0.92 PS 
21 Kunthi 59 F 1.3 NS 
22 Rosammal 68 F 1.21 PS 
23 Subbammal 62 F 1.2 PS 
24 Rasatbi 66 F 1.14 NS 
25 Kanagam 71 F 1.08 PS 
26 Ganesh 40 M 1.2 NS 
27 Rammathal 63 F 0.85 PS 
28 Lakshmiammal 67 F 1.02 NS 
29 Parvathy 54 F 1.18 NS 
30 Tamilselvi 49 F 0.92 PS 
31 Kannan 68 M 0.96 PS 
32 Gracyamma 70 F 1.15 NS 
33 Padmaraj 66 M 1.14 NS 
34 Kuppammal 69 F 1.26 PS 
35 Karthikeyan 73 M 1.28 NS 
36 Premalatha 59 F 1.06 PS 
37 Venkatesh 64 M 1.08 PS 
38 Rajesh 61 M 1.36 NS 
39 Joe 63 M 1.07 NS 
40 Maheshwari 39 F 0.94 PS 
41 Bhavani 74 F 0.98 NS 
42 Ramanathan 65 M 0.99 NS 
43 Sasikala 69 F 1.36 NS 
44 Janaki 60 F 0.94 PS 
45 Sakthi 58 F 0.98 PS 
46 Sukumaran 72 M 1.4 NS 
47 Devaki 57 F 0.98 NS 
48 Lakshmi 64 F 1.08 PS 
49 Hemalatha 66 F 1.12 NS 
50 Indrani 57 F 1.24 NS 
51 Sukumaran 65 M 0.92 NS 
52 Krishnan Nair  58 M 0.98 NS 
53 Shylaja 44 F 1.24 NS 
54 Krishnammal 76 F 0.8 NS 
55 Rasathiammal 62 F 1.38 NS 
56 Geetha  55 F 1.04 NS 
57 Poovathal 69 F 1.08 NS 
58 Devaki 61 F 1.03 PS 
59 Kavitha 39 F 1.12 NS 
60 Nagaraj 68 M 0.98 NS 
61 Ruckmaniammal 65 F 1.28 NS 
62 Palaniammal 74 F 1.36 NS 
63 Savithridevi  62 F 0.98 NS 
64 Murugan 67 M 1.02 NS 
65 Nirmala 65 F 0.96 PS 
66 Rajeswari 56 F 1.21 PS 
67 Rangaraj 71 M 0.94 NS 
68 Sukumari 64 F 1.01 PS 
69 Kaliyammal 69 F 1.04 PS 
70 Ramasamy 54 M 1.14 NS 
71 Pappammal 63 F 1.08 NS 
72 Jeeva 57 F 0.98 PS 
73 Rathinabai  51 F 0.94 PS 
74 Rangagounder 70 M 1.04 NS 
75 Fathima 63 F 1.36 NS 
76 Nancy  42 F 1.34 PS 
77 Narayanasamy 68 M 1.06 NS 
78 Govindammal 64 F 0.94 PS 
79 Murali 60 M 0.96 NS 
80 Janakaraj 50 M 1.33 NS 
81 Rathinbai 69 F 1.24 NS 
82 Savithri 70 F 1.25 PS 
83 Sakthivel  39 M 1.28 NS 
84 Rani  67 F 1.14 NS 
85 Shanthi 74 F 0.98 PS 
86 Kanagaraj  60 M 1.06 NS 
87 Rosy  66 F 0.98 PS 
88 Rangasamy 58 M 0.95 NS 
89 Sivanandan 45 M 1.08 NS 
90 Nesammal 53 F 1.36 NS 
91 Thiyagu  71 M 1.14 NS 
92 Vasantha  62 F 1.28 NS 
93 Divagar 56 M 1 NS 
94 Pandian 68 M 0.79 NS 
95 Selvi  60 F 1.28 NS 
96 Muthupandi 64 M 0.94 NS 
97 Rajakumari  70 F 0.98 PS 
98 Jackuline  43 F 1.28 PS 
99 Janakiammal 99 F 0.81 NS 
100 Peterraj 64 M 1.1 NS 
 
 
